EUCTR2014-002279-27-PL进行中（未招募）1 期
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech Pharmacal Co., Inc.) with Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%(Novartis) in Patients with Osteoarthritis of the Knee.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Ambulatory male and non-pregnant females 35 years and older diagnosed with osteoarthritis according to the American College of Rheumatology Criteria (ACR) (Appendix 2) in one knee.
- •ACR Criteria includes: Knee Pain and at least 3 of the following:
- •1)age = 50
- •2)stiffness lasting < 30 mins
- •3)bony tenderness
- •4)crepitus
- •5)bony enlargement
- •6)no palpable warmth
- •2.Symptom onset of > 6 Months prior to Screening for the target knee.
- •3.If female and of child-bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom + spermicide,
- •4.IUD, oral, transdermal, injected or implanted hormonal contraceptives).
- •5.Periarticular knee pain due to osteoarthritis (not bursitis, tendonitis etc) requiring the use of oral or topical treatments (NSAIDS or acetaminophen) for > 15 days in the 30 days prior to Screening.
- •6.Radiograph of the target knee within the previous year with a Grade 1, 2 or 3 disease based upon the Kellgren-Lawrence disease severity scale (Appendix 3).
- •7.Has baseline pain on movement score of = 50mm on a 100-mm Visual Analogue Scale for the target knee.
- •8.After a 7 day wash out of all pain medication has baseline WOMAC pain sub scale of = 9 on a 5 question, 5 point (0 to 4) Likert scale for the target knee.
- •9.Willing and able to use only acetaminophen as rescue medication.
- •10.Willing and able to comply with the study requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 900
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Females who are pregnant, breast feeding, or planning a pregnancy.
- •2.Radiograph of the target knee within the previous year with a Grade 4 score on the Kellgren-Lawrence disease severity scale (Appendix 3).
- •3.History of osteoarthritis in the contralateral knee requiring medication (OTC or prescription) within 12 months of screening.
- •4.After a 7-day wash out of all pain medication has baseline pain on movement score of = 20mm on a 100-mm Visual Analogue Scale for the contralateral knee immediately prior to randomization.
- •5.Known history of secondary osteoarthritis (e.g. congenital, traumatic, gouty arthritis) or rheumatoid arthritis.
- •6.Known history of other chronic inflammatory diseases, (e.g., colitis) or fibromyalgia.
- •7.History of asthma, hypertension, myocardial infarction, thrombotic events, stroke, congestive heart failure, impaired renal function or liver disease.
- •8.History of coronary artery bypass graft within 6 months of screening.
- •9.Concomitant acetylsalicylic acid therapy other than a stable low dose used for cardiac prophylaxis (max 162mg daily) taken for at least 3 months prior to enrollment and maintained throughout the duration of the study.
- •10.Use of warfarin or other anticoagulant therapy within 30 days of screening.
- •11.Use of ACE inhibitors, cyclosporine, diuretics, lithium or methotrexate, within 30 days of screening or during the study.
- •12.Known history of gastrointestinal bleeding or peptic ulcer disease.
- •13.Abnormal screening clinical laboratory evaluations which the Investigator deems clinically significant.
- •14.Known allergy to aspirin or NSAIDs.
- •15.Skin lesions or wounds in the affected area.
- •16.Significant injury or major knee surgery to either knee within six months prior to screening.
- •17.Results from liver function tests that are more than two times the upper limit of the normal range at screening.
- •18.Any other acute or chronic illness that in the opinion of the investigator could compromise the integrity of study data or place the Patient at risk by participating in the study.
- •19.Concomitant use of corticosteroids (any formulation) or use within 30 days of study randomization.
- •20.Receipt of any drug as part of a research study within 30 days prior to screening.
- •21.Previous participation in this study.
- •22. Known allergy (hypersensitivity) to acetaminophen.
研究者
相似试验
进行中（未招募）
1 期
A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Glucose Transporter Type 1 deficiency syndromeMedDRA version: 17.1 Level: HLGT Classification code 10039911 Term: Seizures (incl subtypes) System Organ Class: 10029205 - Nervous system disordersEUCTR2013-003771-35-GBltragenyx Pharmaceutical Inc36
进行中（未招募）
1 期
Safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (liver disease) from nonalcoholic steatohepatitis (NASH).Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)MedDRA version: 20.0Level: HLTClassification code 10019669Term: Hepatic fibrosis and cirrhosisSystem Organ Class: 100000004871MedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 100000004871EUCTR2019-003932-22-DEBristol-Myers Squibb International Corporation270
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)Perennial Allergic Rhinitis (PAR) in adults and children of 12 years and older.MedDRA version: 9.1Level: LLTClassification code 10034382Term: Perennial allergic rhinitisEUCTR2007-006562-15-EEGlaxoSmithKline Research & Development Ltd288
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor/Idiopathic RhinitisVasomotor/Idiopathic RhinitisEUCTR2004-004744-43-NOGlaxoSmithKline Research & Development Ltd347
进行中（未招募）
1 期
Baricitinib in Patients with COVID-19 InfectioCOVID-19 infectionMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001517-21-DEEli Lilly and Company1,400